MEC Plus Full List View

MEC Plus

Follicular Lymphoma: Defining Best 1L and 2L Treatment in the Era of Personalized Medicine
Follicular Lymphoma: Defining Best 1L and 2L Treatment in the Era of Personalized Medicine
Nakhle Saba, MD
Esophageal, Gastric and GE Junction Tumors: What’s New in 2023?
Esophageal, Gastric and GE Junction Tumors: What’s New in 2023?
Mike Cusnir, MD
EGFRex20ins, METex14 and RET in NSCLC
EGFRex20ins, METex14 and RET in NSCLC
Mark Socinski, MD
Drug Development and New Targeted Agents for Breast Cancer: What Does the Future Hold?
Drug Development and New Targeted Agents for Breast Cancer: What Does the Future Hold?
Mark Pegram, MD
De Novo Acute Myeloid Leukemia
De Novo Acute Myeloid Leukemia
Richard Stone, MD
ctDNA in Lung Cancer: Current State and Future Perspectives
ctDNA in Lung Cancer: Current State and Future Perspectives
Bruna Pellini, MD
ctDNA in Adjuvant and Metastatic Therapy for GI Cancers: Prime Time?
ctDNA in Adjuvant and Metastatic Therapy for GI Cancers: Prime Time?
Olatunji B. Alese, MD, FWACS
Cancer Disparity from Different Angles: How to Tackle It?
Cancer Disparity from Different Angles: How to Tackle It?
John Carpten, PhD
Bringing Personalized Medicine to Colorectal Cancers
Bringing Personalized Medicine to Colorectal Cancers
Michael J. Overman, BS, MD, MHA
Artificial Intelligence in Oncology Care
Artificial Intelligence in Oncology Care
Kristina Rua, MSN, RN, OCN, ONN-CG
ALK: Choosing 1L & Mechanism of Resistance
ALK: Choosing 1L & Mechanism of Resistance
Ibiayi Dagogo-Jack, MD
ADC in NSCLC: TROP2 and HER3 in NSCLC
ADC in NSCLC: TROP2 and HER3 in NSCLC
Hossein Borghaei, MD